A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.
NCT ID: NCT04208763
Last Updated: 2021-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
90 participants
INTERVENTIONAL
2019-12-20
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study design: Randomized controlled trial Study period: August 2019 to December 2021. Sample size: Assuming that the response rate is 90% with GM-CSF and 60% without GM-CSF after day 5. With alpha 5 and power 80,we need to enroll 76 cases (38 cases with each). Further assuming 20 % drop-out due to various reasons, it was decided to enroll 90 cases randomly allocated into two groups (i.e., 45 in each) by block randomization method by taking block size as 6. So for the present study, it was decided to enroll 90 cases in all.
Group A will be given Imipenem and Tigecycline. Patients with recent hospitalisation will be given Colistin in addition.
Group B will be given: To another group we will give Imipenem and Tigecycline and GMCSF.Patients with recent hospitalisation will be given Colistin in addition.
The dose of antibiotic will be given at dosage Inj Imipenem 1gm i.v. TDS Inj Tigecycline 100mg stat f/b 50mg i.v. OD Inj GM-CSF 500mcg s.c. OD Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD Monitoring and assessment At the baseline, all patients will undergo investigational evaluation as described
Daily monitoring of following parameters:
* Haemoglobin,
* Total peripheral leucocyte counts,
* Platelet counts,
* Renal function tests
* Liver function tests and
* Chest X rays will be undertaken
* Ascitic fluid analysis will be done on day 0, day 2 and day 5
Stopping rule:If the patient develops a TLC of more than 50,000, the dose of the GM CSF will be reduced to half and the treatment continued. If, even after the reduction, the TLC rises to more than 50,000, then the treatment will be stopped and the patient excluded.
Expected outcome of the project: Addition of GM-CSF to standard antibiotic regimen helps resolve SBP and improves outcome in decompensated liver cirrhotic patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure
NCT01852630
Comparison of the Efficacy of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis
NCT03702426
Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock
NCT02191475
Efficacy and Safety of Therapy With IgM-enriched Immunoglobulin With a Personalized Dose vs Standard Dose in Patients With Septic Shock.
NCT04182737
Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients
NCT03344627
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Imipenem+Tigecycline+GM-CSF
Imipenem
Inj Imipenem 1gm i.v. TDS
Tigecycline
Inj Tigecycline 100mg stat f/b 50mg i.v. OD
GMCSF
Inj GM-CSF 500mcg s.c. OD
Colistin
Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD
Imipenem+Tigecycline
Imipenem
Inj Imipenem 1gm i.v. TDS
Tigecycline
Inj Tigecycline 100mg stat f/b 50mg i.v. OD
Colistin
Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Imipenem
Inj Imipenem 1gm i.v. TDS
Tigecycline
Inj Tigecycline 100mg stat f/b 50mg i.v. OD
GMCSF
Inj GM-CSF 500mcg s.c. OD
Colistin
Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Hospital acquired SBP with shock
3. Difficult to treat SBP
Exclusion Criteria
2. Cardiac comorbidities (known Coronary Artery Disease)
3. Chronic Kidney Disease on Maintenance Hemodialysis
4. \< 18 years.
5. Advanced Hepatocellular Carcinoma
6. Post liver transplant
7. HIV + ve, Immunosuppressive therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute of Liver and Biliary Sciences, India
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ILBS-SBP-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.